文献速递临床生化临床免疫质量管理与危急值

皮质醇免疫测定与LC-MS/MS方法的全国可比性及实验室间性能评估

National comparability and inter-laboratory performance of cortisol immunoassays and LC-MS/MS methods.
PubMed 文献 · Clin Chem Lab Med · 2026-06-23

该研究分析了45名参与者血清样本,比较Roche、Abbott、Siemens、Beckman Coulter皮质醇免疫测定与LC-MS/MS的一致性及实验室间性能。结果显示Roche、Abbott和Beckman Coulter与LC-MS/MS偏差分别为-3.2%、-6.7%和-5.6%,Siemens原免疫测定偏差25.3%而CSI改进后为4.9%。作者认为基于基础皮质醇浓度范围无需建立全国标准化方案。

要点

  • Roche和Abbott皮质醇免疫测定与LC-MS/MS可比性及实验室间性能可接受。
  • Beckman Coulter免疫测定精密度差,需改进。
  • Siemens CSI改进后显著降低与LC-MS/MS的偏差。

核心结论

  • Roche和Abbott皮质醇免疫测定的测定可比性和实验室间性能可接受。
  • Beckman Coulter免疫测定显示高不精密度,需要改进。
  • Siemens免疫测定经改进(CSI)后与LC-MS/MS的偏差大幅降低。
  • 基于主要处于基础皮质醇浓度范围的人血清结果,无需全国皮质醇测定标准化方案。

研究设计与样本

  • 研究分析了45名参与者的血清样本。
  • 使用Roche Cobas、Abbott Architect/Alinity、Siemens Atellica(含Siemens Atellica CSI)、Beckman Coulter DxI/access免疫测定及LC-MS/MS,每种测定在4-6个实验室进行。
  • 采用Passing-Bablok回归和Bland-Altman分析,并确定每种免疫测定的实验室间性能。

主要发现

  • Roche、Abbott和Beckman Coulter免疫测定与LC-MS/MS的偏差分别为-3.2%、-6.7%和-5.6%。
  • Siemens原免疫测定与LC-MS/MS偏差为25.3%,Siemens CSI测定偏差为4.9%。
  • 实验室间性能:Roche和Abbott可接受,Siemens CSI中等,Beckman Coulter差。
  • 分别有0%、2.3%、12.5%和56.8%的皮质醇测量超过最大允许不精密度。

关键数值与推荐

  • Roche、Abbott和Beckman Coulter免疫测定与LC-MS/MS的偏差分别为-3.2%、-6.7%和-5.6%。
  • Siemens原免疫测定偏差25.3%,Siemens CSI测定偏差4.9%。
  • 超过最大允许不精密度的测量比例分别为0%、2.3%、12.5%和56.8%。

临床怎么用

  • 临床解读动态试验皮质醇结果时应考虑测定方法间的差异。
  • 优先选择与LC-MS/MS可比性及实验室间性能良好的免疫测定(如Roche、Abbott)。
  • 对精密度差的测定(如Beckman Coulter)需改进后再用于临床。

局限性

  • 研究主要使用处于基础皮质醇浓度范围的人血清样本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cortisol measurements are often performed as part of dynamic testing for endocrine disorders. However, considerable variation between cortisol assays may prevent the interchangeability of dynamic test results and interpretation. This study evaluated the comparability and inter-laboratory performance of cortisol immunoassays with that of analytically preferred LC-MS/MS cortisol assays. METHODS: Serum samples from 45 participants were analyzed using Roche Cobas, Abbott Architect/Alinity, Siemens Atellica (including Siemens Atellica CSI), Beckman Coulter DxI/access immunoassays, and LC-MS/MS in 4-6 laboratories per assay. Passing-Bablok regression and Bland-Altman analyses were performed and inter-laboratory performance was determined for each immunoassay. RESULTS: Roche, Abbott and Beckman Coulter immunoassays showed good agreement with LC-MS/MS (bias -3.2 , -6.7 and -5.6 %). The original Siemens immunoassay showed poor agreement (bias 25.3 %), which improved substantially with the Siemens CSI assay (bias 4.9 %). Inter-laboratory performance was acceptable for Roche and Abbott, intermediate for Siemens CSI, but poor for the Beckman Coulter assay. Respectively 0, 2.3, 12.5 and 56.8 % of the cortisol measurements exceeded the maximal allowable imprecision. CONCLUSIONS: Assay comparability and inter-laboratory performance were acceptable for the Roche and Abbott cortisol immunoassays. The Beckman Coulter immunoassay showed high imprecision necessitating improvement. The bias of the Siemens immunoassay vs. LC-MS/MS was strongly reduced following immunoassay improvement (Siemens CSI), demonstrating that significant efforts can lead to much-needed assay improvements. Based on our findings using human sera primarily within the basal cortisol concentration range, we conclude that there is no need for a national standardization program for serum cortisol measurements.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Hillebrand JJ, Bons JAP, van den Berg SAA, et al. National comparability and inter-laboratory performance of cortisol immunoassays and LC-MS/MS methods. Clin Chem Lab Med. 2026. PMID: 42329901. doi:10.1515/cclm-2026-0136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。